Advancing Access to Precision Medicine Act - A Bipartisan Bill

05 March 2018 Personalized Medicine Bulletin Blog
Author(s): Antoinette F. Konski

On February 15, 2018, representatives Eric Swalwell (CA-15), John Shimkus (IL-15), Scott Peters (CA-52), Erik Paulson (MN-03), and Juan Vargas (CA-51), introduced the Advancing Access to Precision Medicine Act (H.R. 5062)(“Bill”) to “provide a study by the National Academy of Medicine on the use of genetic and genomic testing to improve health care, and for other purposes.” (Bill, page 1).  The National Academy of Medicine’s report on its study is due within 3 years from the date of enactment.

Improving Access to Precision Medicine

The Bill directs the Department of Health and Human Services to enter into an agreement with the National Academy of Medicine to recommend how the federal government can support the use of genetic and genomic testing to allow for better delivery of precision medicine, including:

“(A) encouraging the expansion of health insurance coverage of genetic and genomic testing, including diagnostic, predictive, and pre-symptomatic testing, and whole genome sequencing;

(B) supporting the collection of evidence for the clinical utility and appropriate use of genetic and genomic tests;

(C) improving access to genetic counselors, pathologists, and other relevant professionals, including strengthening related workforce education and training efforts;…”

Bill, page 2.

The Bill also requires a report on how coverage provisions in the Medicare and Medicaid programs may restrain the use of genetic testing to improve outcomes for beneficiaries including especially individuals suffering from rare or orphan diseases and individuals in special populations, such as infants, children and the critically ill. The report should include recommendations on how the Centers from Medicare & Medicaid Services can make better determinations to support the use of precision medicine. Bill, pages 2 and 3.

State Option to Provide Whole Genome Sequencing for Certain Children

The Bill allows states to apply for “an exception to the federal medical assistance percentage” to provide qualified children on Medicaid (e.g., those suspected of suffering from a genetic disease) with access to whole genome sequencing. (See February 15, 2018 Swalwell press release.) As a first step, states may apply for a grant to assist them in developing a plan to implement clinical access. Bill, page 6.

Another Step Forward

The Bill, if passed by Congress and signed into law by the President, will further advance the purpose of the 21st Century Cures Act, which authorized funding and allocated resources to advance personalized medicine. The Bill is supported by the Personalized Medicine Coalition, the EveryLife Foundation for Rare Diseases, Biocom, the Advanced Medical Technology Association, and the American Association for Cancer Research. (See February 15, 2018 Swalwell press release).

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.